Dermatomyositis and myastenia gravis: An uncommon association with therapeutic implications
Reumatol Clin. 2015 Jul-Aug;11(4):244-6.
doi: 10.1016/j.reuma.2014.10.002.
Epub 2014 Dec 12.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Reumatología, Hospital Puerta de Hierro-Majadahonda, Majadahonda, Madrid, España.
- 2 Servicio de Reumatología, Hospital Puerta de Hierro-Majadahonda, Majadahonda, Madrid, España. Electronic address: [email protected].
Abstract
The association of dermatomyositis with myasthenia gravis (MG) is uncommon, having been reported so far in only 26 cases. We report the case of a 69 year-old man diagnosed with MG two years ago and currently treated with piridostigmyne. The patient developed acute proximal weakness, shoulder pain and elevated creatine-kinase (CK). He also developed generalized facial erythema and Gottron's papules. Laboratory tests showed positive antinuclear and anti-Mi2 antibodies. Further analysis confirmed CK levels above 1000 U/l. The clinical management of the patient and the therapeutic implications derived from the coexistence of both entities are discusssed.
Keywords:
Dermatomiositis; Dermatomyositis; Inflammatory miopathies; Miastenia gravis; Miopatías inflamatorias; Myasthenia gravis.
Copyright © 2014 Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Aged
-
Cholinesterase Inhibitors / therapeutic use
-
Dermatomyositis / complications*
-
Dermatomyositis / diagnosis
-
Dermatomyositis / drug therapy
-
Drug Therapy, Combination
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Male
-
Methotrexate / therapeutic use
-
Myasthenia Gravis / complications*
-
Myasthenia Gravis / drug therapy
-
Prednisone / therapeutic use
-
Pyridostigmine Bromide / therapeutic use
Substances
-
Cholinesterase Inhibitors
-
Immunosuppressive Agents
-
Pyridostigmine Bromide
-
Prednisone
-
Methotrexate